CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- 4 Grant or award Director acquired 714 shares (grant or award)
- 4 Grant or award Director acquired 714 shares (grant or award)
- 4 Grant or award Director acquired 714 shares (grant or award)
- 4 Grant or award Director acquired 714 shares (grant or award)
- 4 Grant or award Director acquired 714 shares (grant or award)
- 4 Grant or award Director acquired 2,856 shares (grant or award)
- 4 Open-market sale Senior VP, Chief Pharma Dev. sold 1,900 shares at $280.00 ($532,000)
- 4 Open-market sale Senior VP, Chief Pharma Dev. sold 2,000 shares at $285.00 ($570,000)
- 4 Gift Director gave 84,852 shares (gift)
- 4 Open-market sale Senior VP, Chief Pharma Dev. sold 1,036 shares at $231.34 ($239,668)
- 4 Planned sale Director sold 22,489 shares at an average $212.88 ($4,787,404)
- 4 Planned sale Pres., R&D, and CMO sold 2,676 shares at an average $245.99 ($658,258)
- 4 Planned sale Director sold 26,270 shares at an average $246.19 ($6,467,491)
- 4 Planned sale Pres., R&D, and CMO sold 73,888 shares at an average $243.92 ($18,022,588)
- 4 Planned sale Director sold 73,730 shares at an average $243.93 ($17,984,804)
- 4 Planned sale Director sold 11,000 shares at an average $257.48 ($2,832,335)
- 4 Planned sale Director sold 32,489 shares at an average $252.85 ($8,214,998)
- 4 Planned sale Director sold 32,489 shares at an average $252.97 ($8,218,630)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
Page 6 of 29 · 564 filings